Brief: Trevi Therapeutics Announces Positive Topline Results From Study Of Oral Nalbuphine
03/12/2024 22:48
Dec 3 (Reuters) - Trevi Therapeutics Inc TRVI.O :
* TREVI THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM
HUMAN
ABUSE POTENTIAL STUDY OF ORAL NALBUPHINE
* TREVI THERAPEUTICS INC: STATISTICALLY SIGNIFICANT LOWER
"DRUG
LIKING" FOR 81MG AND 162MG DOSES OF ORAL NALBUPHINE VERSUS.
BUTORPHANOL
Source text: ID:nPn7QtRw4a
Further company coverage: TRVI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Trevi Therapeutics
See all newsTrevi Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Trevi Therapeutics Q2 net loss widens on higher R&D costs
Brief: Trevi Therapeutics Q2 Net Income USD -17.797 Million
Trevi Therapeutics Q1 net loss widens as R&D costs rise
Brief: Trevi Therapeutics Q1 Net Income USD -13.192 Million